Mathieu Kerneis

Mathieu Kerneis

Auto-generated profile, based on publicly available information

Mathieu Kerneis

ACTION Study Group, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, La Pitié-Salpêtrière Hospital, Department of Cardiology, Paris, France

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2012 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
JCJean-Philippe Collet
Jean-Philippe Collet
TCThomas Cuisset
Thomas Cuisset
GRGrégoire Rangé
Grégoire Rangé
GCGuillaume Cayla
Guillaume Cayla
SESimon Elhadad
Simon Elhadad
GMGilles Montalescot
Gilles Montalescot
Patients' responses to oral antiplatelet therapy are subject to variation. Bedside monitoring offers the opportunity to improve outcomes after coronary stenting by individualizing therapy.

29 August 2025 in European Heart Journal
Verified
Journal Article
Closed access
JSJeanette Schulz-Menger
Jeanette Schulz-Menger
VCValentino Collini
Valentino Collini
JGJan Wolfgang Gröschel
Jan Wolfgang Gröschel
YAYehuda Adler
Yehuda Adler
ABAntonio Brucato
Antonio Brucato
AKAmayak Kevorkov
Amayak Kevorkov

13 June 2019 in New England Journal of Medicine
Verified
Journal Article
Closed access
JSJoe-Elie Salem
Joe-Elie Salem
YAYves Allenbach
Yves Allenbach
AVAurore Vozy
Aurore Vozy
NBNicolas Brechot
Nicolas Brechot
DJDouglas B. Johnson
Douglas B. Johnson
MKMathieu Kerneis
Mathieu Kerneis
Autoimmune myocarditis is a rare but often fatal complication of immune checkpoint inhibitor therapy for cancer. A case of glucocorticoid-refractory myocarditis in the course of nivolumab treatment for lung cancer was resolved with the use of the cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) agonist abatacept.

6 June 2019 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
BVBirgit Vogel
Birgit Vogel
BCBimmer E. Claessen
Bimmer E. Claessen
SASuzanne V. Arnold
Suzanne V. Arnold
DCDanny Chan
Danny Chan
DCDavid J. Cohen
David J. Cohen
RMRoxana Mehran
Roxana Mehran

1 November 2014 in The Lancet
Verified
Journal Article
Closed access
JCJean-Philippe Collet
Jean-Philippe Collet
JSJohanne Silvain
Johanne Silvain
OBOlivier Barthélémy
Olivier Barthélémy
GRGrégoire Rangé
Grégoire Rangé
GCGuillaume Cayla
Guillaume Cayla
GMGilles Montalescot
Gilles Montalescot

23 February 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
JSJoe-Elie Salem
Joe-Elie Salem
MBMarie Bretagne
Marie Bretagne
BABaptiste Abbar
Baptiste Abbar
SLSarah Leonard-Louis
Sarah Leonard-Louis
SEStéphane Ederhy
Stéphane Ederhy
YAYves Allenbach
Yves Allenbach
Immune-checkpoint-inhibitor (ICI)–associated myotoxicity involves the heart (myocarditis) and skeletal muscles (myositis), which frequently occur concurrently and are highly fatal. We report the results of a strategy that included identification of individuals with severe ICI myocarditis by also screening for and managing concomitant respiratory muscle involvement with mechanical ventilation, as well as treatment with the CTLA4 fusion protein abatacept and the JAK inhibitor ruxolitinib. Forty cases with definite ICI myocarditis were included with pathologic confirmation of concomitant myositis in the majority of patients. In the first 10 patients, using recommended guidelines, myotoxicity-related fatality occurred in 60%, consistent with historical controls. In the subsequent 30 cases, we instituted systematic screening for respiratory muscle involvement coupled with active ventilation and treatment using ruxolitinib and abatacept. The abatacept dose was adjusted using CD86 receptor occupancy on circulating monocytes. The myotoxicity-related fatality rate was 3.4% (1/30) in these 30 patients versus 60% in the first quartile (P < 0.0001). These clinical results are hypothesis-generating and need further evaluation. Significance: Early management of respiratory muscle failure using mechanical ventilation and high-dose abatacept with CD86 receptor occupancy monitoring combined with ruxolitinib may be promising to mitigate high fatality rates in severe ICI myocarditis. See related commentary by Dougan, p. 1040. This article is highlighted in the In This Issue feature, p. 1027